We are live on ! Find out more
EMMA

Emmaus Life Sciences, Inc. Common Stock
EMMA

Delisted

EMMA was delisted on the 10th of September, 2019.

Back to rankings

11 hedge funds and large institutions have $95K invested in Emmaus Life Sciences, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

22% more funds holding

Funds holding: 9 → 11 (+2)

35% less capital invested

Capital invested by funds: $147K → $95K (-$52K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
11
Holders Change
+2
Holders Change %
+22.22%
% of All Funds
0.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$90.2K
2
UBS Group
UBS Group
Switzerland
+$12.1K
3
Macquarie Group
Macquarie Group
Australia
+$5.06K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$72K
2
Bank of America
Bank of America
North Carolina
-$377

EMMA Hedge Fund Activity: Q4 2018 in Review

11 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Emmaus Life Sciences, Inc. Common Stock (EMMA) for Q4 2018, worth a combined $95K — down 35% from $147K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new EMMA positions and 1 closed out — a net gain of 2 holders — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $90.2K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $72K sold.

  • 11 institutional investors held Emmaus Life Sciences, Inc. Common Stock (EMMA) as of Q4 2018, up from 9 in Q3 2018.
  • Funds reported $95K of Emmaus Life Sciences, Inc. Common Stock stock for Q4 2018, down 35% quarter-over-quarter.
  • 3 funds opened new Emmaus Life Sciences, Inc. Common Stock positions in Q4 2018 and 1 closed out, a net change of +2 holders.
  • The largest Emmaus Life Sciences, Inc. Common Stock buyer in Q4 2018 was Citadel Advisors, an estimated $90.2K added.
  • The largest Emmaus Life Sciences, Inc. Common Stock seller in Q4 2018 was Susquehanna International Group, an estimated $72K sold.

Based on aggregated 13F filings for Q4 2018.